The combination of fluticasone furoate and vilanterol trifenatate in the management of asthma: Clinical trial evidence and experience

Research output: Contribution to journalReview article

3 Scopus citations


The treatment of persistent asthma has been aided by the recent approval of new medications. The combined inhaled corticosteroid (ICS)/long-acting β2 agonist (LABA) powder inhaler fluticasone furoate (FF)/vilanterol trifenatate (VI) is one of these new agents, which was recently approved as a maintenance therapy for persistent asthma. This once-daily ICS/LABA inhaler has previously been approved and used in chronic obstructive pulmonary disease as a maintenance therapy. Both FF and VI individually have been shown to have efficacy in the treatment of persistent asthma; the combination of FF/VI at the dose of 100/25 Î1/4g daily improves trough peak expiratory flows and forced expiratory volume in 1 s. It also reduces the frequency of asthma exacerbations in patients with persistent asthma. The once-daily dosing is well tolerated, with limited clinically significant adverse events; the once-daily inhaled dosing regimen should also improve medication adherence. The data supporting the use of the FF/VI inhaler in persistent asthma are reviewed. The dry powder inhaler of FF/VI (100/25 Î1/4g) is an effective and well tolerated once-daily maintenance treatment for patients with persistent asthma.

Original languageEnglish (US)
Pages (from-to)43-56
Number of pages14
JournalTherapeutic Advances in Respiratory Disease
Issue number1
StatePublished - Feb 1 2016



  • combined inhaler
  • fluticasone furoate/vilanterol trifenatate
  • inhaled corticosteroid
  • long-acting β2 agonist
  • persistent asthma
  • powder inhaler

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Pharmacology (medical)

Cite this